# 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

> **NCT00079014** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** triapine
- **DRUG:** doxorubicin hydrochloride
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00079014
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2008-07
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079014, "3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00079014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*